Recent Updates
Recently added Catalysts

MK2461

Phase 1

Advanced Cancer | Small molecule | Oncology |Merck & Company, Inc.|Last Updated: Mar 31, 2015

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment25

FDA Designations

No designations recorded

Clinical trial landscape

MK2461 · 2 trials · 2 indications

Phase 1 2
NCT00496353MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)Neoplasm
COMPLETED26 Analytics
NCT00518739MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)Advanced Cancer
COMPLETED25 Analytics
PHASE1COMPLETED
MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)
Neoplasm
NCT0049635326
Unlock trial analytics
PHASE1COMPLETED
MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)
Advanced Cancer
NCT0051873925
Unlock trial analytics

Study Endpoints

Primary Endpoints

To evaluate the safety and tolerability of MK2461 by assessing incidence of toxicities. Pharmacokinetic and pharmacodynamic parameter will be evaluated.
18 Months
To evaluate the safety and tolerability of MK2461
18 Months

Secondary Endpoints

To evaluate the anti-tumor efficacy of MK2461 in patients with advanced solid tumor by assessing the response rate, progression- free survival, duration of response, time to response and time to progression.
18 Months
To determine the Recommend Phase II Dose or doses (RP2D) based on safety, tumor pharmacodynamics, and parmacokinetics.
18 Months
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
MK2461DRUGMK2461 treatment, bid, 28-day
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Patients must be at least 18 years of age, with adequate organ function, and an ecog performance of \<2 Exclusion Criteria: * No chemotherapy, radiotherapy, or biological therapy with 4 weeks of study participation * Patients must not have primary central nervous system tumo...

Unlock Eligibility Criteria

Competitive Landscape -Cancer 5 trials (matched to "Advanced Cancer")

CompanyTickerTrialsLead PhaseDrugs
GE Healthcare Technologies Inc.GEHC1PHASE1GEH200520/ GEH200521- Part A
Zimmer Biomet Holdings, Inc.ZBH1 - Undisclosed
Ascentage Pharma Group International Unsponsored ADRAAPG1PHASE1Olverembatinib
Unlock Competitive Intelligence

Frequently asked questions about MK2461

What is MK2461 used for?

MK2461 is an investigational small molecule being studied for the treatment of advanced cancer and neoplasms. It is in Phase 1 clinical development for oncology indications. The drug is not approved and remains under investigation.

What does MK2461 target?

MK2461 is a small molecule oncology drug. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being evaluated for its safety and tolerability in patients with advanced solid tumors and other advanced cancers.

Who makes MK2461?

MK2461 is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug in patients with advanced cancer and neoplasms.

What phase is MK2461 in?

MK2461 is in Phase 1 clinical development. Two Phase 1 trials have been completed, one with 26 patients and another with 25 patients. The drug remains investigational and has not received FDA approval.

What clinical trials is MK2461 in?

MK2461 has been studied in two completed Phase 1 trials: NCT00496353, a Phase I/II study in patients with advanced solid tumors, and NCT00518739, a study in patients with advanced cancer. Both trials enrolled adults aged 18 years and older.

Is MK2461 the same as MK-2461?

MK2461 is also referred to as MK-2461 in clinical trial documentation. Both names refer to the same investigational small molecule being developed by Merck & Company for the treatment of advanced cancer and neoplasms.